Rather than trying to edit the many common genetic markers that each have tiny effects, a practical engineering strategy is to find and modify rare, large‑effect variants that strongly shift a trait. This lowers the technical barrier to meaningful changes but concentrates ethical, safety, and governance questions around a smaller set of high‑impact edits.
— If true, this shifts policy debates from broad polygenic regulation to intense scrutiny of rare‑variant discovery, clinical translation, and reproductive use.
2026.03.05
100% relevant
Author cites Nucleus IQ’s 500,000‑marker prediction as insufficient for engineering and uses BRCA1 (a rare variant with large breast‑cancer effect) as an analog for how rare variants could drive big trait changes; also notes sequencing cost collapse (NHGRI data) that enables discovery.
← Back to All Ideas